Atara Biotherapeutics (ATRA) vs OKYO Pharma (OKYO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
OKYO Pharma (OKYO) has outperformed Atara Biotherapeutics (ATRA) over the past year, losing 49.5% versus a loss of 53.7%. Atara Biotherapeutics is the larger company by market cap ($64.5 million vs $56.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATRA | OKYO |
|---|---|---|
| Share price | $6.33 | $1.07 |
| Market cap | $64.49M | $56.15M |
| 1-day change | -0.16% | -7.76% |
| YTD return | -65.01% | -48.31% |
| 1-year return | -53.73% | -49.53% |
| 5-year return | -98.56% | — |
| Forward P/E | 3.96 | — |
| EPS (TTM) | $-1.12 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $120.77M | — |
| Revenue growth (YoY) | -6.33% | — |
| Net income (latest FY) | $32.69M | $-4.71M |
| Operating margin | 29.69% | — |
| Net margin | 27.07% | — |
| 52-week high | $19.15 | $3.20 |
| 52-week low | $3.92 | $1.00 |
| Distance from 52-week high | -66.94% | -66.56% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +115.96% | +678.50% |
| Average volume | 35.46K | 143.41K |
| Shares outstanding | 10.19M | 52.48M |
| Employees | 10 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Atara Biotherapeutics
ATRA stock →Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees
About OKYO Pharma
OKYO stock →OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
ATRA vs OKYO FAQ
Which is bigger, Atara Biotherapeutics or OKYO Pharma?
Atara Biotherapeutics (ATRA) is larger, with a market capitalization of $64.49M compared with $56.15M for OKYO Pharma (OKYO).
Which stock has performed better over the past year, ATRA or OKYO?
OKYO returned -49.53% over the past 12 months, compared with -53.73% for ATRA (price return, excluding dividends). Past performance does not predict future results.
Are Atara Biotherapeutics and OKYO Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.